Chinese researchers took proanthocyanidin C1 (PCC1), a senolytic polyphenol from grape seed that clears senescent cells but is barely absorbed when swallowed, and reformulated it into a grape seed extract preparation they call NSPCC1. Fed to old mice, the reformulated extract reached the bloodstream far better than ordinary grape seed extract, extended median survival by at least 10 percent, reduced pro-inflammatory myeloid skewing of blood stem cells, and cut macrophage infiltration and fibrosis in liver, kidney, and lung. The core claim is that fixing the bioavailability of a food-derived senolytic, and acting through the bone marrow, produces measurable systemic anti-aging effects. The work is preliminary, industry-co-authored, and reports effects without absolute lifespan numbers or formal effect sizes.
The senolytic idea, clearing out the worn-out cells that accumulate with age and poison their neighbors with inflammatory signals, has become one of the more credible bets in aging biology. PCC1, a polyphenol found in grape seeds, is one of the natural compounds that can do this. Its problem has always been practical rather than biological: when you swallow it, almost none of it gets into your blood, so earlier work had to inject it to see effects.
This study, from Jinan University in Guangzhou together with the research arm of the supplement company By-Health, attacks that problem head-on. The team used a modified grape seed extraction process to concentrate PCC1 and, they argue, to protect it through digestion. The resulting formulation, NSPCC1, delivered substantially more PCC1 into the bloodstream of rats than conventional grape seed extract did, while the pure compound on its own was essentially not absorbed at all.
The bigger idea sits downstream of that. The researchers focused on the bone marrow, the body’s blood and immune cell factory. With age, blood stem cells drift toward making inflammatory myeloid cells at the expense of the lymphoid cells that support adaptive immunity. This myeloid bias is now seen as an engine of chronic, low-grade inflammation, sometimes called inflammaging, that damages organs throughout the body.
Feeding 18-month-old mice the NSPCC1 diet nudged that balance back. Treated animals produced relatively fewer myeloid cells and more B cells, formed more colonies in stem cell assays, and showed improved red blood cell measures and higher antioxidant glutathione. In parallel, their livers, kidneys, and lungs carried fewer inflammatory M1 macrophages and less scar-like fibrosis, and their liver gene-expression profiles shifted back toward those of young mice. Median survival rose by at least 10 percent.
The framing is appealing: rather than targeting one organ, improve the output of the blood system and let the benefits propagate outward through what the authors call the stem cell to circulation to multi-organ aging axis. Whether that story holds up depends on details the paper mostly does not provide, including absolute lifespan numbers, causal proof, and effect sizes. It is a promising signal from a group with a commercial interest in the product, not a finished result.
Actionable Insights
The practical take-home for a human today is thin, and the honest headline is a translational gap. The intervention is a specific proprietary grape seed extract formulation, NSPCC1, not ordinary grape seed extract off a shelf, and not PCC1 capsules, which the paper shows are almost unabsorbed when taken by mouth (oral PCC1 standard exposure was described as negligible).
Effect size and real-world magnitude. The mouse dose was 2 g/kg per day of NSPCC1, standardized to 1 percent PCC1, equal to 20 mg/kg of PCC1. Converting the mouse dose to a human-equivalent dose using standard body-surface-area scaling (multiply by roughly 3/37) gives about 162 mg/kg, or close to 9 to 10 g of this specific formulation per day for a 60 kg adult, delivering on the order of 95 to 100 mg of PCC1. That is a large daily intake of a single extract, and no human has been tested. The survival benefit was reported only as at least 10 percent longer median survival, with no absolute days, no maximum lifespan, and no hazard ratio, so the true magnitude cannot be pinned down. The clearest reproducible signals were mechanistic and histological (less organ fibrosis, fewer M1 macrophages, restored myeloid-to-lymphoid balance, higher glutathione), not a validated human outcome.
Bottom line. Nothing here justifies buying grape seed supplements for longevity. The usable insight is directional: oral bioavailability is the rate-limiting problem for polyphenol senolytics, and the bone marrow is a plausible high-leverage target.
Context and Source
- Open Access Paper: Hematopoietic Rejuvenation via Natural Senolytic NSPCC1 Delays Inflammatory Aging.
- Institutions: Jinan University (State Key Laboratory of Bioactive Molecules and Druggability Assessment; Institute of Aging and Regenerative Medicine), Guangzhou, China. A second affiliation is the BY-HEALTH Institute of Nutrition and Health, Guangzhou, a commercial supplement company that also supplied the test material. Three authors are employed by By-Health Co. Ltd., a declared conflict of interest.
- Country: China.
- Journal: Biology (MDPI), Basel, Switzerland. Published 12 June 2026, volume 15, article 922. Academic editor: Ricardo Villa-Bellosta.
- Impact evaluation: The 2025 Journal Impact Factor for Biology (MDPI) is 4.3 (5-year IF 4.6). The impact score of this journal is 4.3, therefore this is a Low-to-Medium impact journal.